Biohm Health Secures $4.52M Series B Funding to Revolutionize Microbiome Innovation

Biohm Technologies, a pioneering leader based in Cleveland, OH, has recently celebrated a major milestone by raising $4,520,000 in fresh funding. This significant investment underpins the company’s mission to revolutionize gut health through targeted microbiome products. Unlike most players in the industry that focus solely on bacterial populations, Biohm distinguishes itself by leveraging a comprehensive dataset that encompasses both bacterial and fungal populations in the gut. Their innovative approach is powered by Symbiont™, a data-driven methodology that has already garnered acclaim by validating award-winning ingredients through rigorous clinical trials. At the heart of their portfolio is Mycohsa™, the first probiotic blend of its kind that harnesses advanced data analytics to break down digestive biofilms and support a balanced gut ecosystem by targeting both bacteria and yeasts. The fresh funds will fast-track the development of novel products and support further enhancements in Biohm’s state-of-the-art microbiome gut testing kits, available as a private label solution for health and wellness brands. This funding will also facilitate expanded research initiatives, enabling the refinement of Symbiont™ to explore new therapeutic avenues in gut health. As consumer interest escalates in personalized health solutions and innovative approaches to wellness, Biohm is poised to reshape the narrative around digestive health with groundbreaking, scientifically validated products. With this infusion of capital, the company is not only set to accelerate its product pipeline but also reinforce its commitment to offering trusted, data-driven innovations that empower individuals to achieve optimal gut health.